<DOC>
	<DOCNO>NCT00400205</DOCNO>
	<brief_summary>This Phase II study design test efficacy chemotherapy docetaxel , cisplatinum ( cisplatin ) 5-fluorouracil patient squamous cell carcinoma oral cavity determine effect agent may cancer cell .</brief_summary>
	<brief_title>Study Induction Docetaxel , Cisplatin 5-Fluorouracil</brief_title>
	<detailed_description>This Phase II study design test efficacy chemotherapy docetaxel , cisplatinum , 5-fluorouracil patient squamous cell carcinoma oral cavity determine effect agent may cancer cell . Approximately 60 patient take part multi-sites potentially 20 patient participate Emory Winship Cancer Institute Atlanta , Georgia .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Mouth Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>Histologically cytologically proven squamous cell carcinoma oral cavity . Primary tumor site eligible : oral cavity . Although admittedly squamous cell type , follow tumor exclude responsiveness chemotherapy may differ : tumor nasal paranasal cavity nasopharynx . Oral cavity tumor mandible invasion exclude tumor biology management tumor complex likely include upfront surgical resection . Stage 3 4 disease without evidence distant metastasis verify chest xray , abdominal ultrasound , CT scan ( liver function test abnormality ) ; bone scan case local symptom . At least one uni bidimensionally measurable lesion . Age ≥ 18 year . WHO ( World Health Organization ) performance status 2 less . No active alcohol addiction . Final eligibility clinical trial determine health professional conduct trial . Pregnant breast feed Previous malignancy site , exception adequately treat situ carcinoma cervix uterus , basal , squamous cell carcinoma skin cancer curatively treat surgery evidence disease least 5 year . Any prior treatment radiotherapy chemotherapy exclusion criterion . Patients experience involuntary weight loss 25 % body weight 2 month precede study entry . Concurrent treatment anticancer therapy . Participation investigational trial within 30 day study entry . Patients history severe hypersensitivity reaction Taxotere® drug formulate polysorbate 80 . No previous chemotherapy radiotherapy reason previous surgery SCCHN [ squamous cell carcinoma head neck ] ( biopsy ) allow time study entry . Final eligibility clinical trial determine health professional conduct trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>Squamous Cell Carcinoma Oral Cavity</keyword>
</DOC>